US46583P1021 - Common Stock
IVERIC bio Inc
NASDAQ:ISEE (7/10/2023, 7:00:03 PM)
After market: 39.94 -0.01 (-0.03%)39.95
+0.15 (+0.38%)
IVERIC bio, Inc. operates as a biopharmaceutical company. The company is headquartered in Parsippany, New Jersey and currently employs 74 full-time employees. The company went IPO on 2013-09-25. The firm is focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Its lead asset is its clinical-stage product candidate, avacincaptad pegol, which is also referred to as ACP or Zimura, a complement C5 inhibitor. Zimura is targeting diseases including geographic atrophy (GA), intermediate age-related macular degeneration (AMD), and autosomal recessive Stargardt disease (STGD1). In addition to ACP, the Company is also developing its preclinical product candidate, IC-500, a high temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA secondary to AMD and potentially other age-related retinal diseases. Its portfolio also includes several ongoing gene therapy research programs, each of which uses adeno-associated virus (AAV) for gene delivery. These AAV mediated gene therapy programs are targeting the orphan inherited retinal diseases (IRDs).
IVERIC bio Inc
8 Sylvan Way, Suite 2372
Parsippany NEW JERSEY 10001
P: 16094746755.0
CEO: Glenn P. Sblendorio
Employees: 74
Website: https://ivericbio.com/
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the...
Iveric Bio (ISEE) ticked up 0.8% in after hours trading after saying it expects its sale to Astellas (ALPMF) to close on July 11
Iveric Bio (ISEE), which agreed to be acquired by Astellas Pharmaceuticals (ALPMF) in May for $5.9 billion, dropped as much as 8.8%, though it has now pared the loss to 3%
Iveric Bio (ISEE) rose 2.2% after the HSR waiting period for its planned sale to Astellas Pharmaceuticals (ALPMY) expired
Here you can normally see the latest stock twits on ISEE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: